

**510(k) Summary**  
**21 CFR 807.92(a)****Niagara®, Niagara® Slim-Cath®, Brevia®**  
Dual Lumen Catheters  
Prepared January 14, 2009**FEB 12 2009****General  
Provisions**

Submitter of 510(k)  
Premarket Notification: Bard Access Systems, Inc. (BAS)  
[Subsidiary of C.R. Bard, Inc.]  
Salt Lake City, Utah 84116  
Phone: (801) 522-5000, Ext. 5651  
Fax: (801) 522-5425

Contact Person: Jessica Agnello  
Regulatory Affairs Specialist

Device Trade Name: **Niagara®, Niagara® Slim-Cath®, Brevia®**  
Device Generic Name: Short-Term Hemodialysis Catheter

Trade Name: **Niagara® Catheters**  
Common/Usual Name: Short-Term Hemodialysis Catheter  
Classification Name: 78 MPB-Catheter, Hemodialysis,  
Non-Implanted  
CFR Reference: 21 CFR §876.5540(b)(2), Class II  
Classification Panel: Gastroenterology and Urology  
Premarket Notification: See below

Predicate Device Name	510(k)	Concurrence Date
<b>Niagara® Short Term Dialysis Catheters</b>	K965178	August 19, 1997

**Predicate  
Devices**

Trade Name: **Niagara® Slim-Cath® Catheters**  
Common/Usual Name: Short-Term Hemodialysis Catheter  
Classification Name: 78 MPB-Catheter, Hemodialysis,  
Non-Implanted  
CFR Reference: 21 CFR §876.5540(b)(2), Class II  
Classification Panel: Gastroenterology and Urology  
Premarket Notification: See below

Predicate Device Name	510(k)	Concurrence Date
<b>Niagara® Slim-Cath® Short Term Dialysis Catheters</b>	K010778	April 13, 2001

Trade Name: **Brevia® Catheters**  
Common/Usual Name: Short-Term Hemodialysis Catheter  
Classification Name: 78 MPB-Catheter, Hemodialysis,  
Non-Implanted  
CFR Reference: 21 CFR §876.5540(b)(2), Class II  
Classification Panel: Gastroenterology and Urology  
Premarket Notification: See below

Predicate Device Name	510(k)	Concurrence Date
Brevia <sup>®</sup> Short Term Dialysis Catheters	K881743	June 23, 1988

**Classification** 21 CFR §876.5540(b)(2), Class II,  
78 MPB-Catheter, Hemodialysis, Non-Implanted

---

**Performance Standards** Performance standards have not been established by FDA under section 514 of the Federal Food, Drug and Cosmetic Act.

---

**Intended Use** The Niagara<sup>®</sup>, Niagara<sup>®</sup> Slim-Cath<sup>®</sup>, Brevia<sup>®</sup> Dual Lumen Catheters recommended for use in attaining temporary vascular access for hemodialysis, apheresis, and hemoperfusion treatments. Intended for insertion in the subclavian, internal jugular, or femoral vein as required.  
*The intended use has not changed from the predicate catheters.*

---

**Indications for Use** The Niagara<sup>®</sup>, Niagara<sup>®</sup> Slim-Cath<sup>®</sup>, Brevia<sup>®</sup> Dual Lumen Catheters are indicated for use in attaining short-term (less than 30 days) vascular access for hemodialysis, hemoperfusion, and apheresis therapy via the jugular, subclavian or femoral vein.  
*The indications for use has not changed from the predicate catheters.*

---

**Technological Characteristics** Technological similarities between the subject Niagara<sup>®</sup>, Niagara<sup>®</sup> Slim-Cath<sup>®</sup>, Brevia<sup>®</sup> Dual Lumen catheters and the predicate devices remain identical. There are no new questions raised regarding safety or efficacy of the subject Niagara<sup>®</sup>, Niagara<sup>®</sup> Slim-Cath<sup>®</sup>, Brevia<sup>®</sup> Dual Lumen catheters.

---

**Summary of Substantial Equivalence** Based on the indications for use, technological characteristics, and safety and performance testing, the subject Niagara<sup>®</sup>, Niagara<sup>®</sup> Slim-Cath<sup>®</sup>, Brevia<sup>®</sup> Dual Lumen catheters met the minimum requirements that are considered adequate for its intended use and is substantially equivalent in design, materials, sterilization, principles of operation and indications for use to current commercially available catheters/cited predicates.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Jessica Agnello  
Regulatory Affairs Specialist  
C. R. Bard, Inc.  
Bard Access Systems  
605 North 5600 West  
SALT LAKE CITY UT 84116

FEB 12 2009

Re: K090102

Trade/Device Name: **Niagara<sup>®</sup>, Niagara<sup>®</sup> Slim-Cath<sup>®</sup>, and Brevia<sup>®</sup> Dual Lumen Catheters**  
Regulation Number: 21 CFR §876.5540  
Regulation Name: Blood access device and accessories  
Regulatory Class: II  
Product Code: MPB  
Dated: January 14, 2009  
Received: January 15, 2009

Dear Ms. Agnello:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act). You may, therefore, market the device, subject to the general controls provisions of Act. However, you are responsible to determine that the medical devices you use as components in the kit have either been determined as substantially equivalent under the premarket notification process (Section 510(k) of the act), or were on the market prior to May 28, 1976, the enactment date of the Medical Device Amendments. *Please note:* If you purchase your device components in bulk (i.e., unfinished) and further process (e.g., sterilize) you must submit a new 510(k) before including these components in your kit. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807);

labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

In addition, we have determined that your device kit contains Lidocaine HCL 1% and Sodium Chloride Solution, which are subject to regulation as drugs.


Our substantially equivalent determination does not apply to the drug component[s] of your device. We recommend you first contact the Center for Drug Evaluation and Research before marketing your device with the drug component[s]. For information on applicable Agency requirements for marketing these drugs, we suggest you contact:

Director, Division of Drug Labeling Compliance (HFD-310)  
Center for Drug Evaluation and Research  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857  
(301) 594-0101

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation, please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll free number (800) 638-2041 or (240) 276-3150, or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Janine M. Morris  
Acting Director, Division of Reproductive,  
Abdominal, and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known):

Device Name:

Niagara®, Niagara® Slim-Cath®,  
Brevia® Dual Lumen Catheters

Indications for Use:

The **Niagara®**, **Niagara® Slim-Cath®**, and **Brevia®** Dual Lumen Catheters are indicated for use in attaining short-term (less than 30 days) vascular access for hemodialysis, hemoperfusion, and apheresis therapy via the jugular, subclavian or femoral vein.


Prescription Use   
(Part 21 CFR §801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR §801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE OF  
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
\_\_\_\_\_  
(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices  
510(k) Number K090102